Atrial natriuretic peptide increases urinary albumin excretion in people with normoalbuminuric type-2 diabetes

Ir J Med Sci. 2007 Jul-Sep;176(2):67-73. doi: 10.1007/s11845-007-0030-1. Epub 2007 May 3.

Abstract

Background: Atrial natriuretic peptide (ANP) is elevated in patients with type-2 diabetes and microalbuminuria. The purpose of this study is to evaluate if ANP increases Urinary Albumin Eaxcretion Rate (UAER) in type-2 diabetes.

Methods: Eight normoalbuminuric diabetic subjects underwent a randomised single blind study of 60 min intravenous infusion of ANP or vehicle. Eight non-diabetic controls underwent ANP infusion alone. Seven normoalbuminuric type-2 diabetes subjects received further ANP infusions during euglycaemia and during hyperglycaemia.

Results: ANP increased urinary sodium (191.3 +/- 80.7 to 529.2 +/- 263.4 mumol/min, mean +/- SD, and P < 0.001) and UAER (72.2 +/- 73.4 to 224.9 +/- 182.9.5 mug/min, and P < 0.01) in diabetic subjects. In controls, UAER did not change significantly (P = 0.16); however, the natriuretic response to ANP was similar to diabetic subjects (P = 0.98). Hyperglycaemic did not enhance the albuminuric response to ANP (P = 0.88).

Conclusion: ANP increases UAER in normoalbuminuric type-2 diabetic subjects.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Albuminuria / physiopathology*
  • Atrial Natriuretic Factor / administration & dosage
  • Atrial Natriuretic Factor / blood
  • Atrial Natriuretic Factor / physiology*
  • Cyclic GMP / urine
  • Diabetes Mellitus, Type 2 / physiopathology*
  • Diabetes Mellitus, Type 2 / urine*
  • Female
  • Humans
  • Hyperglycemia / physiopathology
  • Infusions, Intravenous
  • Kidney / physiopathology
  • Male
  • Middle Aged
  • Single-Blind Method
  • Sodium / urine

Substances

  • Atrial Natriuretic Factor
  • Sodium
  • Cyclic GMP